Abstract
The use of bortezomib as a treatment modality of AHR improved and stabilized graft function (clinical response) in the majority of patients. Its use in single dose, even combined with rituximab, does not seem to be useful to obtain a sustained clinical response, or to reduce HLAabs level. The use of 4 doses of bortezomib in days 1, 4, 7, and 10 (1.3 mg/m2 BSA each) plus plasmapheresis produced both a good clinical response and a reduction in DSA. Moving forward, it will be necessary to define the long-term effectiveness of bortezomib and whether rituximab administration is indispensable to achieve this goal. Until now, it is evident that many patients needed retreatment and they were well tolerated.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Academies and Institutes*
-
Acute Disease
-
Adult
-
Boronic Acids / administration & dosage
-
Boronic Acids / therapeutic use*
-
Bortezomib
-
Drug Administration Schedule
-
Female
-
Graft Rejection / immunology
-
Graft Rejection / prevention & control*
-
Graft Survival / drug effects*
-
HLA Antigens / immunology
-
Humans
-
Immunity, Humoral / drug effects*
-
Immunosuppressive Agents / administration & dosage
-
Immunosuppressive Agents / therapeutic use*
-
Isoantibodies / blood
-
Kidney Transplantation / immunology*
-
Male
-
Mexico
-
Middle Aged
-
Plasmapheresis
-
Protease Inhibitors / administration & dosage
-
Protease Inhibitors / therapeutic use*
-
Proteasome Endopeptidase Complex / metabolism
-
Proteasome Inhibitors
-
Pyrazines / administration & dosage
-
Pyrazines / therapeutic use*
-
Time Factors
-
Treatment Outcome
-
Young Adult
Substances
-
Boronic Acids
-
HLA Antigens
-
Immunosuppressive Agents
-
Isoantibodies
-
Protease Inhibitors
-
Proteasome Inhibitors
-
Pyrazines
-
Bortezomib
-
Proteasome Endopeptidase Complex